Table 3.
Risk factors for nivolumab-induced pneumonitis in patients with solid tumors by univariate and multivariate logistic regression analysis
| Univariate model | Multivariate model | ||||||
|---|---|---|---|---|---|---|---|
| OR | (95% CI) | P-value | OR | (95% CI) | P-value | ||
| Age, years | ≥65 vs. < 65 | 3.05 | (1.08–10.90) | 0.034 | 1.53 | (0.44–6.11) | 0.51 |
| Sex | Male vs. female | 10.13 | (2.03–183.77) | 0.0018 | 5.58 | (1.01–104.40) | 0.049 |
| Smoking status | Current/ex-smoker vs. Never-smoker | 1.52 | (0.53–5.50) | 0.45 | |||
| Performance status | ≥2 vs. 0 or 1 | 0.75 | (0.17–2.38) | 0.64 | |||
| Tumor types | NSCLC vs. HNC/GC | 1.79 | (0.73–4.70) | 0.21 | |||
| Pre-existing ILD | Yes vs. No | 9.42 | (3.67–25.80) | < 0.0001 | 5.92 | (2.07–18.54) | 0.0008 |
| NLRa | ≥2.5 vs. < 2.5 | 0.87 | (0.35–2.22) | 0.76 | |||
| ≥5.0 vs. < 5.0 | 0.68 | (0.21–1.82) | 0.45 | ||||
| LDH (IU/l) | ≥240 vs. < 240 | 1.52 | (0.59–3.74) | 0.37 | |||
| CRP (mg/dl) | ≥1 vs. < 1 | 0.71 | (0.27–1.75) | 0.46 | |||
Sq squamous cell carcinoma, ILD interstitial lung disease, NLR neutrophil-to-lymphocyte ratio, LDH lactate dehydrogenase, CRP C-reactive protein, OR odds ratio, CI confidence interval
aOne patient with HNC was excluded because NLR was not performed